Niagen (NAGE) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$129.1M

Revenue (quarter)

$29.8M

Revenue growth (year over year)

−4.28%

Gross profit (trailing twelve months)

$82.9M

Gross margin

64.24%

Net income (trailing twelve months)

$16.0M

Net income (quarter)

$963,000.00

Net income growth (year over year)

−73.32%

Net margin

12.39%

Return on equity

21.80%

EPS (trailing twelve months)

$0.20

Book value per share

$1.05

P/E (trailing twelve months)

12.77

Price to book

2.47

Debt to assets

22.57%

Payout ratio

—

Dividend yield

—

Company profile

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

• Is Niagen (NAGE) profitable?

  Yes. Niagen earned $16.0M in net income over the trailing twelve months, a net margin of 12.39%.

• How much revenue does Niagen (NAGE) make?

  Niagen generated $129.1M in revenue over the trailing twelve months, down 4.28% year over year.

• What is NAGE's P/E ratio?

  Niagen trades at 12.8 times trailing twelve-month earnings, on an EPS of $0.20.

• How do I buy stock in Niagen (NAGE)?

  NAGE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.